EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ginsenoside Rh3 enhances regorafenib efficacy in hepatocellular carcinoma by modulating FGFR4-STAT3-YAP signaling pathway

Youngsic Jeon, Hyukjoon Kwon, Jeong Eun Yoo, Keunwan Park, Taek Chung, Young Nyun Park, Jinchan Sim, Taejung Kim, Jungyeob Ham, Young-Joo Kim

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.117679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Youngsic Jeon und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Natural Products, Korea Institute of Science and Technology, the Republic of Korea. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ginsenosides, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, National Research Foundation of Korea, Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efforts to develop more effective and safer cancer therapies have driven growing interest in combination treatments using well-established agents. Here we investigate whether ginsenoside Rh3, a bioactive constituent of Panax ginseng, enhances the anticancer properties of regorafenib, a multikinase inhibitor, in hepatocellular carcinoma (HCC). Although ginsenosides are primarily recognized for immunomodulatory and antioxidant properties, their wider therapeutic applications, particularly in oncology, are being actively investigated. Among the ginsenosides tested, ginsenosides Rh3 produced the greatest reduction in HCC cell viability when combined with regorafenib. To elucidate the basis of synergy, we conducted proteomic profiling using phosphor-kinase activity assay; the combination of regorafenib and ginsenoside Rh3 attenuated phosphorylation of signal transducer and activator of transcription 3 (STAT3) and concomitantly upregulated pro-apoptotic proteins. These effects were associated with inactivation of FGFR4 and JAK2, key regulators of cell growth and apoptosis, and dependent on blocking STAT3 nuclear translocation. Notably, the combination treatment also suppressed TEA domain family transcription factor (TEAD)-dependent transcription without promoting nuclear accumulation of yes-associated protein (YAP). The findings suggest that the observed synergy in HCC is linked to inhibition of the FGFR4/JAK2/STAT3 axis and attenuation of YAP-TEAD transcriptional activity, warranting further clinical evaluation of this combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorGinsenosidesCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsPyridinesReceptor, Fibroblast Growth Factor, Type 4Transcription FactorsAdaptor Proteins, Signal TransducingPhosphoproteinsHumansSignal TransductionAnimalsDrug SynergismCell Line, TumorYAP-Signaling ProteinsHep G2 Cells

Stichwörter der Autor:innen

ApoptosisCombination therapyGinsenoside Rh(3)Hepatocellular carcinomaRegorafenib

Substanzen

STAT3 Transcription FactorGinsenosidesPhenylurea CompoundsSTAT3 protein, humanPyridinesregorafenibReceptor, Fibroblast Growth Factor, Type 4FGFR4 protein, humanTranscription FactorsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Institute of Natural Products, Korea Institute of Science and Technology, the Republic of Korea.
  • Department of Pathology, Yonsei University College of Medicine, the Republic of Korea. Electronic address: yoojeongeun@yuhs.ac.
  • Institute of Natural Products, Korea Institute of Science and Technology, the Republic of Korea. Electronic address: keunwan@kist.re.kr.
  • Department of Pathology, Yonsei University College of Medicine, the Republic of Korea.
  • Department of Pathology, Yonsei University College of Medicine, the Republic of Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, the Republic of Korea; Graduate School of Medical Sci…
  • Institute of Natural Products, Korea Institute of Science and Technology, the Republic of Korea; Natural Product Applied Science, KIST School, University of Science and Technology, the Republic of Korea.

Förderung

  • Ministry of Education
  • National Research Foundation of Korea
  • Korea Institute of Science and Technology

Zitieren

APA

Jeon, Y., Kwon, H., Yoo, J. E., Park, K., Chung, T., Park, Y. N., Sim, J., Kim, T., Ham, J., & Kim, Y. J. (2026). Ginsenoside Rh3 enhances regorafenib efficacy in hepatocellular carcinoma by modulating FGFR4-STAT3-YAP signaling pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117679

Vancouver

Jeon Y, Kwon H, Yoo JE, Park K, Chung T, Park YN, et al. Ginsenoside Rh3 enhances regorafenib efficacy in hepatocellular carcinoma by modulating FGFR4-STAT3-YAP signaling pathway. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117679

BibTeX
@article{Jeon2026,
  author = {Jeon, Youngsic and Kwon, Hyukjoon and Yoo, Jeong Eun and Park, Keunwan and Chung, Taek and Park, Young Nyun and Sim, Jinchan and Kim, Taejung and Ham, Jungyeob and Kim, Young-Joo},
  title = {Ginsenoside Rh3 enhances regorafenib efficacy in hepatocellular carcinoma by modulating FGFR4-STAT3-YAP signaling pathway},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.117679}
}
Kostenlos starten →